会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 82. 发明授权
    • Compositions and diagnostic methods using monoclonal antibodies against
CD44v6
    • 使用针对CD44v6的单克隆抗体的组合物和诊断方法
    • US5616468A
    • 1997-04-01
    • US453378
    • 1995-05-30
    • Marko SalmiSirpa Jalkanen
    • Marko SalmiSirpa Jalkanen
    • C12N15/02A61K39/395C07K14/705C07K16/28C12P21/08C12R1/91G01N33/574
    • C07K14/70585C07K16/2884C07K2317/34C07K2319/00Y10S436/813
    • CD44 is a family of glycoproteins involved in cell-cell and cell-matrix interactions. In addition to the major 90 kD form present on most hematopoietic cells, larger forms are found on keratinocytes and carcinoma cell lines. These bigger isoforms of CD44 arise by alternative splicing that results in insertion of one or more of the "variant" exons into the extracellular part of the 90 kD constant form of the molecule. Antibodies were raised against a synthetic peptide containing a sequence encoded by the human exon 6A mAb thus obtained (designated Var3.1) strongly reacted with the plasma membranes of squamous cells in upper layers of skin and tonsil surface epithelia. Weaker staining was seen in germinal centers, vascular endothelia and enterocytes. CD44v6 was absent from tissue leukocytes and connective tissue components. In comparison, Hermes-3 epitope (on the constant part) containing forms of CD44 were preferentially localized in basal layers of epithelia, present on the surface of most leukocytes and connective tissue cells, and undetectable on the luminal surface of high endothelial venules. In benign neoplasms, epithelial cells stained with mAb Var3.1 like in normal tissues. In contrast, immunostaining of 30 squamous carcinoma specimens (both primary and metastatic lesions) revealed that malignant transformation resulted in down-regulation or disappearance of Var3.1 epitope, but in majority of cases, not in diminished expression of the Hermes-3 epitope. An examination of serum samples from normal individuals and from patients with inflammatory diseases indicated that CD44v6 was increased in samples from patients with rheumatoid arthritis or inflammatory bowel disease.
    • CD44是参与细胞和细胞 - 基质相互作用的糖蛋白家族。 除了存在于大多数造血细胞上的主要90kD形式之外,在角质形成细胞和癌细胞系上发现较大的形式。 CD44的这些更大的同种型通过选择性剪接产生,导致一个或多个“变体”外显子插入分子的90kD恒定形式的胞外部分。 针对包含由如此获得的人外显子6AmAb编码的序列(指定为Var3.1)的合成肽产生抗体,其与上皮层和扁桃体表面上皮中的鳞状细胞的质膜强烈反应。 在生发中心,血管内皮和肠细胞中观察到较弱的染色。 组织白细胞和结缔组织组分中不存在CD44v6。 相比之下,含有CD44形式的Hermes-3表位(在恒定部分上)优先定位于大多数白细胞和结缔组织细胞表面存在的上皮基底层,并且在高内皮小静脉的腔表面上不可检测。 在良性肿瘤中,上皮细胞用正常组织中的mAb Var3.1染色。 相比之下,30个鳞状细胞癌标本(原发性和转移性病变)的免疫染色显示,恶性转化导致Var3.1表位的下调或消失,但在绝大多数情况下,Hermes-3表位的表达不会降低。 来自正常个体和炎性疾病患者血清样本的检查表明,来自类风湿性关节炎或炎症性肠病患者的样品中CD44v6增加。